127 related articles for article (PubMed ID: 29374382)
1. Zinc Supplementation Does Not Affect Glucagon Response to Intravenous Glucose and Insulin Infusion in Patients with Well-Controlled Type 2 Diabetes.
Pérez A; Rojas P; Carrasco F; Basfi-Fer K; Pérez-Bravo F; Codoceo J; Inostroza J; Ruz M
Biol Trace Elem Res; 2018 Oct; 185(2):255-261. PubMed ID: 29374382
[TBL] [Abstract][Full Text] [Related]
2. Effects of intraduodenal hydroxycitrate on glucose absorption, incretin release, and glycemia in response to intraduodenal glucose infusion in health and type 2 diabetes: A randomised controlled trial.
Thazhath SS; Wu T; Bound MJ; Checklin HL; Standfield S; Jones KL; Horowitz M; Rayner CK
Nutrition; 2016 May; 32(5):553-9. PubMed ID: 26792024
[TBL] [Abstract][Full Text] [Related]
3. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
Fineman M; Weyer C; Maggs DG; Strobel S; Kolterman OG
Horm Metab Res; 2002 Sep; 34(9):504-8. PubMed ID: 12384827
[TBL] [Abstract][Full Text] [Related]
4. Effect of insulin-glucose infusions on plasma glucagon levels in fasting diabetics and nondiabetics.
Raskin P; Fujita Y; Unger RH
J Clin Invest; 1975 Nov; 56(5):1132-8. PubMed ID: 1184740
[TBL] [Abstract][Full Text] [Related]
5. Abnormal alpha cell function in diabetics response to insulin.
Unger RH; Madison LL; Muller WA
Diabetes; 1972 May; 21(5):301-7. PubMed ID: 24683634
[TBL] [Abstract][Full Text] [Related]
6. Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
Ehlers MR; Klaff LJ; D'Alessio DA; Brazg R; Kay HD; Harley RE; Mathisen AL; Schneider R
Horm Metab Res; 2003 Oct; 35(10):611-6. PubMed ID: 14605997
[TBL] [Abstract][Full Text] [Related]
7. Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.
de la Peña A; Loghin C; Cui X; Zhang X; Kapitza C; Kelly RP
Diabetes Obes Metab; 2017 Apr; 19(4):517-523. PubMed ID: 27976833
[TBL] [Abstract][Full Text] [Related]
8. On the role of the gut in diabetic hyperglucagonaemia.
Lund A
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385175
[TBL] [Abstract][Full Text] [Related]
9. Indomethacin does not affect endogenous glucose production in type 2 diabetes mellitus.
Pereira Arias AM; Bisschop PH; Ackermans MT; Endert E; Romijn JA; Sauerwein HP
Horm Metab Res; 2001 Nov; 33(11):659-63. PubMed ID: 11733868
[TBL] [Abstract][Full Text] [Related]
10. Improvement in insulin sensitivity following intensive insulin therapy and association of glucagon with long-term diabetes remission.
Zhang B; Chen YY; Yang ZJ; Wang X; Li GW
J Int Med Res; 2016 Dec; 44(6):1543-1550. PubMed ID: 27834301
[TBL] [Abstract][Full Text] [Related]
11. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
Christensen MB
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187
[TBL] [Abstract][Full Text] [Related]
12. Zinc supplementation in prediabetes: A randomized double-blind placebo-controlled clinical trial.
Ranasinghe P; Wathurapatha WS; Galappatthy P; Katulanda P; Jayawardena R; Constantine GR
J Diabetes; 2018 May; 10(5):386-397. PubMed ID: 29072815
[TBL] [Abstract][Full Text] [Related]
13. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Hare KJ
Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
[TBL] [Abstract][Full Text] [Related]
14. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
15. Circulating insulin inhibits glucagon secretion induced by arginine in type 1 diabetes.
Oskarsson PR; Lins PE; Ahré B; Adamson UC
Eur J Endocrinol; 2000 Jan; 142(1):30-4. PubMed ID: 10633218
[TBL] [Abstract][Full Text] [Related]
16. Hypoglycemic and Hypolipidemic Effects of Leucine, Zinc, and Chromium, Alone and in Combination, in Rats with Type 2 Diabetes.
Sadri H; Larki NN; Kolahian S
Biol Trace Elem Res; 2017 Dec; 180(2):246-254. PubMed ID: 28409409
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
Egan JM; Meneilly GS; Habener JF; Elahi D
J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
[TBL] [Abstract][Full Text] [Related]
18. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
Kolterman OG; Buse JB; Fineman MS; Gaines E; Heintz S; Bicsak TA; Taylor K; Kim D; Aisporna M; Wang Y; Baron AD
J Clin Endocrinol Metab; 2003 Jul; 88(7):3082-9. PubMed ID: 12843147
[TBL] [Abstract][Full Text] [Related]
19. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.
Hompesch M; Jones-Leone A; Carr MC; Matthews J; Zhi H; Young M; Morrow L; Reinhardt RR
Diabetes Obes Metab; 2015 Jan; 17(1):82-90. PubMed ID: 25263215
[TBL] [Abstract][Full Text] [Related]
20. Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.
Polderman JA; Houweling PL; Hollmann MW; DeVries JH; Preckel B; Hermanides J
BMC Anesthesiol; 2014; 14():91. PubMed ID: 25419179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
